SCHEMBL6317152

SCHEMBL6317152

CC(C)=CC(=O)Nc1onc(-c2nccs2)c1C(N)=O

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
LMNA P02545 1/20 0.36
TP53 P04637 1/20 0.36
HPGD P15428 1/20 0.36
PTGS2 P35354 3/20 0.36
ALDH1A1 P00352 2/20 0.35
POLB P06746 1/20 0.35
AHR P35869 1/20 0.35
HTT P42858 1/20 0.34
TNIK Q9UKE5 3/20 0.33
RAB9A P51151 2/20 0.33
KDM4E B2RXH2 1/20 0.33
NPC1 O15118 1/20 0.33
PTK2 Q05397 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6317960 0.80 RET (0.41) SMN1; SMN2MEN1KMT2ALMNATP53
SCHEMBL6317093 0.78 ADORA2A (0.42) SMN1; SMN2MEN1KMT2AHPGDALDH1A1
SCHEMBL6323617 0.78 ADORA2A (0.41) SMN1; SMN2MEN1KMT2AHPGDALDH1A1
SCHEMBL6318529 0.78 TDP1 (0.40) SMN1; SMN2LMNATP53HPGDALDH1A1
SCHEMBL6316058 0.78 NPC1 (0.38) SMN1; SMN2LMNATP53HPGDALDH1A1
SCHEMBL6317926 0.78 ADORA2A (0.49) HTTNPC1
SCHEMBL6318109 0.77 MAPK14 (0.46) SMN1; SMN2MEN1KMT2AHPGDALDH1A1
SCHEMBL6317525 0.77 NPC1 (0.50) SMN1; SMN2MEN1KMT2ALMNATP53
SCHEMBL6317526 0.77 ALDH1A1 (0.36) LMNAHPGDALDH1A1RAB9ANPC1
SCHEMBL6315040 0.77 RET (0.40) SMN1; SMN2MEN1KMT2AALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 SMN1; SMN2 2766/4885MEN1 2789/4885KMT2A 1089/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.